Pds Biotechnology Corp Stock Buy Hold or Sell Recommendation
| PDSB Stock | USD 3.20 0.21 7.02% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding PDS Biotechnology Corp is 'Cautious Hold'. Macroaxis provides PDS Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PDSB positions. The advice algorithm takes into account all of PDS Biotechnology's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting PDS Biotechnology's buy or sell advice are summarized below:
Real Value 7.15 | Target Price 19.14 | Hype Value 3.23 | Market Value 3.2 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell PDS Biotechnology Corp given historical horizon and risk tolerance towards PDS Biotechnology. When Macroaxis issues a 'buy' or 'sell' recommendation for PDS Biotechnology Corp, the advice is generated through an automated system that utilizes algorithms and statistical models.
PDS |
Execute PDS Biotechnology Buy or Sell Advice
The PDS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on PDS Biotechnology Corp. Macroaxis does not own or have any residual interests in PDS Biotechnology Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute PDS Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
PDS Biotechnology Trading Alerts and Improvement Suggestions
| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86. | |
| PDS Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from forbes.com: AI At The Edge The Key To Becoming A Data-Driven Business |
PDS Biotechnology current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. PDS analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. PDS analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
PDS Biotechnology Returns Distribution Density
The distribution of PDS Biotechnology's historical returns is an attempt to chart the uncertainty of PDS Biotechnology's future price movements. The chart of the probability distribution of PDS Biotechnology daily returns describes the distribution of returns around its average expected value. We use PDS Biotechnology Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of PDS Biotechnology returns is essential to provide solid investment advice for PDS Biotechnology.
| Mean Return | -0.39 | Value At Risk | -9.16 | Potential Upside | 10.11 | Standard Deviation | 5.69 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of PDS Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
PDS Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PDS Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PDS Biotechnology Corp backward and forwards among themselves. PDS Biotechnology's institutional investor refers to the entity that pools money to purchase PDS Biotechnology's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2023-12-31 | 120.7 K | Two Sigma Advisers, Llc | 2023-12-31 | 109.1 K | Bank Of New York Mellon Corp | 2023-12-31 | 107.7 K | Nuveen Asset Management, Llc | 2023-12-31 | 105.2 K | Citadel Advisors Llc | 2023-09-30 | 96 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 85.1 K | Bank Of America Corp | 2023-12-31 | 85 K | Charles Schwab Investment Management Inc | 2023-12-31 | 77.2 K | Commonwealth Equity Services Inc | 2023-12-31 | 77 K | Blackrock Inc | 2023-12-31 | 1.9 M | Vanguard Group Inc | 2023-12-31 | 1.5 M |
PDS Biotechnology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 12.1M | 16.7M | 36.4M | 8.6M | (17.3M) | (16.4M) | |
| Free Cash Flow | (18.1M) | (13.1M) | (12.5M) | (25.7M) | (33.6M) | (35.3M) | |
| Depreciation | 98.4K | 15.6K | 5.4K | 86.0 | 57.3K | 52.6K | |
| Other Non Cash Items | (9.4M) | 160.7K | 241.0K | 5.5M | 3.8M | 4.0M | |
| Net Income | (7.0M) | (14.8M) | (16.9M) | (40.9M) | (42.9M) | (45.1M) | |
| End Period Cash Flow | 12.2M | 28.8M | 65.2M | 73.8M | 56.6M | 61.8M | |
| Investments | (188.7K) | 0.0 | 29.4M | 275.0K | 316.3K | 300.4K | |
| Net Borrowings | 16.7K | (15.6K) | 25M | 24.6M | 28.2M | 15.9M | |
| Change To Netincome | (6.6M) | 613.0K | 4.4M | 5.2M | 6.0M | 6.3M |
PDS Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to PDS Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that PDS Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PDS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.68 | |
β | Beta against NYSE Composite | 3.56 | |
σ | Overall volatility | 5.59 | |
Ir | Information ratio | -0.08 |
PDS Biotechnology Volatility Alert
PDS Biotechnology Corp exhibits very low volatility with skewness of 0.12 and kurtosis of 0.07. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure PDS Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact PDS Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.PDS Biotechnology Fundamentals Vs Peers
Comparing PDS Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze PDS Biotechnology's direct or indirect competition across all of the common fundamentals between PDS Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as PDS Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of PDS Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare PDS Biotechnology to competition |
| Fundamentals | PDS Biotechnology | Peer Average |
| Return On Equity | -1.22 | -0.31 |
| Return On Asset | -0.39 | -0.14 |
| Current Valuation | 76.96 M | 16.62 B |
| Shares Outstanding | 36.68 M | 571.82 M |
| Shares Owned By Insiders | 3.67 % | 10.09 % |
| Shares Owned By Institutions | 22.95 % | 39.21 % |
| Number Of Shares Shorted | 6.15 M | 4.71 M |
| Price To Earning | 24.70 X | 28.72 X |
| Price To Book | 4.47 X | 9.51 X |
| EBITDA | (42.99 M) | 3.9 B |
| Net Income | (42.94 M) | 570.98 M |
| Cash And Equivalents | 52.98 M | 2.7 B |
| Cash Per Share | 1.86 X | 5.01 X |
| Total Debt | 23.85 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 12.34 X | 2.16 X |
| Book Value Per Share | 0.79 X | 1.93 K |
| Cash Flow From Operations | (33.64 M) | 971.22 M |
| Short Ratio | 4.76 X | 4.00 X |
| Earnings Per Share | (1.39) X | 3.12 X |
| Price To Earnings To Growth | (0.05) X | 4.89 X |
| Target Price | 14.4 | |
| Number Of Employees | 25 | 18.84 K |
| Beta | 1.72 | -0.15 |
| Market Capitalization | 109.67 M | 19.03 B |
| Total Asset | 59.39 M | 29.47 B |
| Retained Earnings | (144.5 M) | 9.33 B |
| Working Capital | 45.43 M | 1.48 B |
| Current Asset | 39.11 M | 9.34 B |
| Current Liabilities | 4.54 M | 7.9 B |
| Net Asset | 59.39 M |
Note: Acquisition by Richard Sykes of 9000 shares of PDS Biotechnology at 3.9 subject to Rule 16b-3 [view details]
PDS Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PDS . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 79230.48 | |||
| Daily Balance Of Power | 0.8077 | |||
| Rate Of Daily Change | 1.07 | |||
| Day Median Price | 3.12 | |||
| Day Typical Price | 3.15 | |||
| Price Action Indicator | 0.19 | |||
| Period Momentum Indicator | 0.21 |
About PDS Biotechnology Buy or Sell Advice
When is the right time to buy or sell PDS Biotechnology Corp? Buying financial instruments such as PDS Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 2.2M | 8.3M | 2.4M | 3.7M | Total Assets | 67.2M | 77.0M | 59.4M | 64.9M |
Use Investing Ideas to Build Portfolios
In addition to having PDS Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Natural Foods Thematic Idea Now
Natural Foods
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
| View All Next | Launch |
Check out PDS Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for PDS Stock analysis
When running PDS Biotechnology's price analysis, check to measure PDS Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PDS Biotechnology is operating at the current time. Most of PDS Biotechnology's value examination focuses on studying past and present price action to predict the probability of PDS Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PDS Biotechnology's price. Additionally, you may evaluate how the addition of PDS Biotechnology to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is PDS Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Return On Assets (0.39) | Return On Equity (1.22) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.